Articles
Saluda raises $10m for neuromodulation device
NICTA spinoff Saluda Medical has raised $10m in Series B funding to help develop Evoke, its neuromodulation device for treating chronic pain and other conditions. [ + ]
Cynata achieves world-first MSC breakthrough
Cynata Therapeutics (ASX:CYP) has validated a potentially revolutionary method of efficiently manufacturing mesenchymal stromal cells using induced pluripotent stem cells. [ + ]
Gravity explains why cells are microscopic
The average animal cell is 10 µm across - why? Why aren't they bigger? [ + ]
DIY: How to measure Planck's constant using LEGO
The kilogram is about to be redefined using Planck's constant and you can now measure this constant yourself with a little 'do-it-yourself' effort and some LEGO. [ + ]
DIY: How to measure Planck's constant using Lego
The kilogram is about to be redefined using Planck's constant and you can now measure this constant yourself with a little 'do-it-yourself' effort and some Lego. [ + ]
Sirtex profit grows 58% in 1H15
Sirtex Medical (ASX:SRX) has reported a 58.1% increase in net profit for the first half of FY15 as a result of stronger sales of its SIR-Spheres microspheres. [ + ]
Immuron licenses Travelan in China region
Immuron (ASX:IM) has licensed its Travelan product - a preventative treatment for travellers diarrhoea - in China and expects the market to eclipse sales of the product in its other regions combined. [ + ]
Novel activity identified for an existing drug
Drug discovery company Re-Pharm has used computational chemistry suite Forge, a product of its parent company Cresset, to identify novel anti-inflammatory activity for an existing drug which is widely prescribed for other non-inflammatory conditions. [ + ]
CSL boosts half-year profit by 7%
CSL (ASX:CSL) has reported a net profit for the first half of FY15 of $890.3m, with sales increasing across all its core product segments.
[ + ]Glucose-responsive insulin to better control diabetes
Researchers from MIT have developed a new type of insulin which activates in the bloodstream only when it is needed. The development could make everyday life much easier for type 1 diabetes patients. [ + ]
Mesoblast well funded despite rising losses
Mesoblast (ASX:MSB) reported a 64% higher net loss for the half-year ending in December, but still ended the period in a strong cash position of $149.2m. [ + ]
The mystery of the disappearing bees revealed?
It's no secret that honey bee populations have been rapidly declining of late. An international group of scientists, including Australians, thinks the cause of this collapse lies in young bees who are growing up too fast.
[ + ]Prescient acquires cancer biomarker p27
Prescient (ASX:PTX) has acquired the exclusive global rights to the p27 biomarker and plans to develop it as a companion diagnostic to cancer drug candidate PTX-100. [ + ]
New structural variant of carbon made of pentagons
Researchers from the US and China have discovered a structural variant of carbon called 'penta-graphene' - a very thin sheet of pure carbon that resembles the pentagonal pattern of the tiles which pave the streets of Cairo. [ + ]